Cagrilintide: evaluating investigational product claims

Educational information only — not medical advice. This material cannot diagnose a condition, recommend treatment, or replace care from a qualified clinician who knows your history. The Peptide Center uses an evidence-first editorial process that prioritizes primary regulatory sources, trial registries, and peer-reviewed research; uncertainty and evidence limits should be part of every health claim.

Cagrilintide may be discussed alongside metabolic-health research. FDA states that it is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. Review the current FDA information rather than relying on social-media claims or ingredient names alone.